- Lonza plans to expand its drug-linker center of excellence and payload-linker manufacturing capacity at its Visp site to support clinical and commercial ADC programs.
- The expansion will add commercial-scale capabilities for highly potent active pharmaceutical ingredients (HPAPIs) and ADC payload-linkers, with the facility expected to be operational in 2028.
Lonza has announced plans to expand its drug-linker center of excellence and payload-linker manufacturing capacity at its Visp site in Switzerland. The investment will add commercial-scale capabilities for the manufacture of highly potent active pharmaceutical ingredients (HPAPIs) and antibody-drug conjugate (ADC) payload-linkers, further expanding the company’s integrated CDMO and contract manufacturing offering for ADC therapies.
The expansion will add manufacturing capacity within an existing GMP facility, including payload-linker production and purification capabilities, as well as dedicated analytical and process development laboratories. According to the company, the multipurpose facility has been designed to support flexible production of a broad range of payload-linker molecules and can be further expanded with additional manufacturing suites as customer demand increases.
Lonza said the new capacity will be integrated with its existing ADC manufacturing network in Visp, which includes monoclonal antibody manufacturing, conjugation, and drug product manufacturing capabilities in Visp and Stein, Switzerland. The expansion will also be supported by additional quality control capacity for highly potent payload-linker molecules.
The company expects the facility to become operational in 2028 and support both clinical and commercial manufacturing programs. The additional capacity is intended to help customers accelerate the development and commercialization of ADC therapies by providing integrated manufacturing services across the product lifecycle.
“The rapid growth of the ADC market is driving increasing demand for highly complex payload-linkers that require advanced manufacturing capabilities. This investment reflects that commitment by expanding our capacity to support this next generation of therapies and enabling our customers to progress efficiently from development to commercial supply.”
Christian Seufert, Head of Advanced Synthesis at Lonza
